AntriaBio Delaware, Inc. f/k/a AntriaBio, Inc. ("AntriaBio Delaware"), a biopharmaceutical company developing novel therapeutics for the diabetes market, is pleased to announce the closing of its planned and previously announced merger with AntriaBio, Inc. f/k/a Fits My Style Inc., a Nevada corporation. Following the merger, the company is now listed as AntriaBio, Inc. ("AntriaBio"), and trading on the OTC Bulletin Board and the OTCQB under the symbol "FMYY." In connection with the merger, AntriaBio appointed three new directors.
Sanofi and Bristol-Myers Squibb Company today announced they have restructured their successful long-term alliance following the loss of exclusivity of Plavix and Avapro/Avalide in many major markets.
The Paris-based pharma behemoth, Sanofi-Aventis, leads the second-largest health-care acquisition of 2010 with its proposed purchase of Genzyme Corp., one of the world’s leading biotech players. The European Union has recently announced its approval for the proposed $18.5 billion deal, however, the deal has been held up as Genzyme considers the $69 per share offer as too low. Industry insiders speculate that this deal will soon be worked out.
From Associated Press (July 8, 2010)
NEW YORK -- Alcon Inc.’s Independent Director Committee said Thursday it created a litigation trust with $50 million for litigation related to any deal between Alcon and a majority shareholder, with a focus on Novartis.
The trust was formed to provide funds to commence, defend or maintain a lawsuit. Novartis currently owns about 23 percent of Alcon and is trying to buy the company. It has offered up to $39 billion for Alcon.